top of page

๐Ÿ“ˆ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐…๐ฅ๐š๐ฌ๐ก ๐Ÿ“‰

๐“๐ก๐ž ๐‚๐จ๐ซ๐จ๐ง๐š ๐๐ข๐ฅ๐ฅ


๐“๐ก๐ž ๐”๐’ ๐ฉ๐ก๐š๐ซ๐ฆ๐š๐œ๐ž๐ฎ๐ญ๐ข๐œ๐š๐ฅ ๐œ๐จ๐ฆ๐ฉ๐š๐ง๐ฒ $MRK (Merck & Co.) ๐ก๐š๐ฌ ๐ฌ๐ฎ๐œ๐œ๐ž๐ฌ๐ฌ๐Ÿ๐ฎ๐ฅ๐ฅ๐ฒ ๐ญ๐ž๐ฌ๐ญ๐ž๐ ๐š ๐ง๐ž๐ฐ ๐š๐œ๐ญ๐ข๐ฏ๐ž ๐ฌ๐ฎ๐›๐ฌ๐ญ๐š๐ง๐œ๐ž ๐š๐ ๐š๐ข๐ง๐ฌ๐ญ ๐‚๐จ๐ฏ๐ข๐. ๐‡๐ข๐ ๐ก ๐๐ž๐ฆ๐š๐ง๐ ๐ข๐ฌ ๐ž๐ฑ๐ฉ๐ž๐œ๐ญ๐ž๐. ๐–๐ก๐š๐ญ ๐ข๐ฌ ๐ญ๐ก๐ž ๐ฉ๐ข๐ฅ๐ฅ ๐ฐ๐จ๐ซ๐ญ๐ก? ๐€๐ง ๐š๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ.


A corona agent developed by the US pharmaceutical company Merck & Co. has shown encouraging results in clinical trials: ๐“๐ก๐ž ๐ซ๐ข๐ฌ๐ค ๐จ๐Ÿ ๐›๐ž๐ข๐ง๐  ๐ก๐จ๐ฌ๐ฉ๐ข๐ญ๐š๐ฅ๐ข๐ฌ๐ž๐ ๐ฐ๐ข๐ญ๐ก ๐œ๐จ๐ฏ๐ข๐ ๐๐ข๐ฌ๐ž๐š๐ฌ๐ž ๐ฐ๐š๐ฌ ๐ซ๐ž๐๐ฎ๐œ๐ž๐ ๐›๐ฒ ๐Ÿ“๐ŸŽ ๐ฉ๐ž๐ซ๐œ๐ž๐ง๐ญ ๐›๐ฒ ๐ญ๐š๐ค๐ข๐ง๐  ๐Œ๐จ๐ฅ๐ง๐ฎ๐ฉ๐ข๐ซ๐š๐ฏ๐ข๐ซ. Fatalities did not occur. Merck and its development partner Ridgeback are now hoping for accelerated approval. This could happen in the USA by the end of the year.


Although there are already drugs to treat covid, Molnupiravir would fill a gap: The drug can be easily administered as a pill and helps at-risk patients who show symptoms but are not yet so severely ill that they need to be hospitalised. The drug Remdesivir from the biotech company $GILD (Gilead Sciences Inc) , on the other hand, is used for patients who are already suffering from severe symptoms. Antibody cocktails like those developed by $REGN (Regeneron Pharmaceuticals) are administered by infusion and are therefore expensive to use. Merck's new active ingredient could therefore significantly relieve the burden on the healthcare system.


From the stock market's point of view, the drug's sales potential is particularly interesting. An agreement with the US authorities gives an indication. ๐€๐œ๐œ๐จ๐ซ๐๐ข๐ง๐  ๐ญ๐จ ๐ญ๐ก๐ข๐ฌ ๐š๐ ๐ซ๐ž๐ž๐ฆ๐ž๐ง๐ญ, ๐Œ๐ž๐ซ๐œ๐ค ๐ฐ๐ข๐ฅ๐ฅ ๐ฌ๐ฎ๐ฉ๐ฉ๐ฅ๐ฒ ๐ญ๐š๐›๐ฅ๐ž๐ญ๐ฌ ๐Ÿ๐จ๐ซ ๐Ÿ.๐Ÿ• ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐ญ๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ๐ฌ. ๐“๐ก๐ž ๐ฉ๐ซ๐ข๐œ๐ž ๐Ÿ๐จ๐ซ ๐ญ๐ก๐ข๐ฌ ๐ฉ๐š๐œ๐ค๐š๐ ๐ž ๐ข๐ฌ ๐Ÿ.๐Ÿ ๐›๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐จ๐ฅ๐ฅ๐š๐ซ๐ฌ, ๐ฐ๐ก๐ข๐œ๐ก ๐œ๐จ๐ซ๐ซ๐ž๐ฌ๐ฉ๐จ๐ง๐๐ฌ ๐ญ๐จ ๐Ÿ•๐ŸŽ๐ŸŽ ๐๐จ๐ฅ๐ฅ๐š๐ซ๐ฌ ๐ฉ๐ž๐ซ ๐ญ๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ. The US company (which is completely independent of the German Merck KGaA, not tradable on eToro) also announced that it wants to produce ten million doses by the end of the year. So that could amount to a sales potential of seven billion dollars. According to data from the financial service Bloomberg, analysts had recently included around two billion dollars each for the current and coming year in their forecasts.


๐ƒ๐ซ๐ฎ๐  ๐ข๐ฌ ๐š ๐ฏ๐š๐ฅ๐ฎ๐š๐›๐ฅ๐ž ๐š๐๐๐ข๐ญ๐ข๐จ๐ง ๐ญ๐จ ๐ญ๐ก๐ž ๐œ๐จ๐ฆ๐ฉ๐š๐ง๐ฒ'๐ฌ ๐ฅ๐ข๐ง๐ž-๐ฎ๐ฉ

Merck turned over 48 billion dollars last year. The top performer was the cancer drug Keytruda with 14.4 billion dollars. Molnupiravir could become the second strongest product in the US company's medicine cabinet. However, there are still question marks. So far, little is known about possible side effects. In addition, the drug is not suitable for every patient. From the stock market's point of view, it is also important what price Merck will actually be able to charge for future deliveries. Competition is likely to become more intense. Among others, the Swiss pharmaceutical giant $ROG.ZU (Roche Holding Ltd) (also in our portfolio) has a Covid drug in the pipeline.


For the American Merck, Molnupiravir, as soon as the active ingredient is approved, should be an important growth accelerator. According to data compiled by Bloomberg, the company expects group sales to increase by an average of around six percent by 2024, and adjusted profits by around twelve percent. The potential of Molnupiravir is likely to be cautiously calculated. Besides, the Dow Jones-listed stock offers a dividend yield of more than three per cent, even after the recent price increase.


๐“๐ก๐ž ๐ฌ๐ก๐š๐ซ๐ž ๐ซ๐ž๐š๐œ๐ญ๐ž๐ ๐ญ๐จ ๐ญ๐ก๐ž ๐ง๐ž๐ฐ๐ฌ ๐ฐ๐ข๐ญ๐ก ๐š ๐ฌ๐ข๐ ๐ง๐ข๐Ÿ๐ข๐œ๐š๐ง๐ญ ๐ฃ๐ฎ๐ฆ๐ฉ ๐ข๐ง ๐ฉ๐ซ๐ข๐œ๐ž, ๐›๐ฎ๐ญ ๐ข๐ฌ ๐ฌ๐ญ๐ข๐ฅ๐ฅ ๐ฆ๐จ๐๐ž๐ซ๐š๐ญ๐ž๐ฅ๐ฒ ๐ฏ๐š๐ฅ๐ฎ๐ž๐.


I wish you all an exciting and fullfilling week!


BR


www.oboi-invest.com/

bottom of page
>
    
    <script type=